Search research articles
Contact Us
Filters
Showing results (11-20 of 82) with videos related to
Page
of 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2007
Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib
Philip J Saylor, Tony R Reid
The Lancet. Oncology
|
April 17, 2010
Prostate-cancer-associated hypercoagulability: do we need to worry about androgen deprivation?
Philip J Saylor, Annemarie E Fogerty
The Oncologist
|
January 24, 2012
Should the denosumab metastasis prevention trial change practice for men with nonmetastatic prostate cancer?
Philip J Saylor, M Dror Michaelson
Prostate Cancer and Prostatic Diseases
|
November 11, 2009
Bone health and prostate cancer
P J Saylor, M R Smith
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 27, 2009
New treatments for renal cell carcinoma: targeted therapies
Philip J Saylor, M Dror Michaelson
Nature Reviews. Urology
|
October 7, 2009
Prostate cancer: How can we improve the health of men who receive ADT?
Philip J Saylor, Matthew R Smith
The Journal of Urology
|
March 17, 2009
Metabolic complications of androgen deprivation therapy for prostate cancer
Philip J Saylor, Matthew R Smith
Genes, Brain, and Behavior
|
August 7, 2008
Amphetamine-induced locomotion and gene expression are altered in BDNF heterozygous mice
A J Saylor, J F McGinty
Healthcare Financial Management : Journal of the Healthcare Financial Management Association
|
December 11, 1986
Developing a solid base for a cost accounting system
A J Baptist, J Saylor, J Zerwekh
Clinical Genitourinary Cancer
|
March 3, 2012
Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy
Philip J Saylor, Bernard Escudier, M Dror Michaelson
Page
of 9
Search research articles
Search
Showing results (11-20 of 82) with videos related to
Sort By:
Page
of 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2007
Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib
Philip J Saylor, Tony R Reid
The Lancet. Oncology
|
April 17, 2010
Prostate-cancer-associated hypercoagulability: do we need to worry about androgen deprivation?
Philip J Saylor, Annemarie E Fogerty
The Oncologist
|
January 24, 2012
Should the denosumab metastasis prevention trial change practice for men with nonmetastatic prostate cancer?
Philip J Saylor, M Dror Michaelson
Prostate Cancer and Prostatic Diseases
|
November 11, 2009
Bone health and prostate cancer
P J Saylor, M R Smith
Journal of the National Comprehensive Cancer Network : JNCCN
|
June 27, 2009
New treatments for renal cell carcinoma: targeted therapies
Philip J Saylor, M Dror Michaelson
Nature Reviews. Urology
|
October 7, 2009
Prostate cancer: How can we improve the health of men who receive ADT?
Philip J Saylor, Matthew R Smith
The Journal of Urology
|
March 17, 2009
Metabolic complications of androgen deprivation therapy for prostate cancer
Philip J Saylor, Matthew R Smith
Genes, Brain, and Behavior
|
August 7, 2008
Amphetamine-induced locomotion and gene expression are altered in BDNF heterozygous mice
A J Saylor, J F McGinty
Healthcare Financial Management : Journal of the Healthcare Financial Management Association
|
December 11, 1986
Developing a solid base for a cost accounting system
A J Baptist, J Saylor, J Zerwekh
Clinical Genitourinary Cancer
|
March 3, 2012
Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy
Philip J Saylor, Bernard Escudier, M Dror Michaelson
Page
of 9